Matt Gline, Roivant CEO (Credit: Roivant)
Roivant announces study win in eye disease for Pfizer asset, plans $1.5B share buyback
Roivant has found a use for its extra cash, and is revealing the latest data from the big pharma relationship that helped generate those funds …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
